The treatment of hormone-induced early-stage avascular necrosis of the femoral head (ANFH) with transplantation of hepatocyte growth factor (HGF)-transgenic bone marrow stromal stem cells (BMSCs) was examined. A rabbit model of hormone-induced early ANFH was first established. BMSCs were transplanted by core decompression under the guidance of computed tomography (CT). A supportive fibrinogen drug delivery mixture (FG) was tested for mechanical enhancement of stem cell delivery. Therapeutic efficacy was evaluated by CT, magnetic resonance imaging (MRI), CT perfusion imaging, ink artery infusion angiography, hematoxylin-and-eosin staining and immunohistochemical staining for extracellular signal-regulated kinase-1/2 of pathological sections. A regular arrangement of trabeculae and obvious bone regeneration were observed in the animals receiving transplanted transgenic BMSCs with FG. Newly generated capillaries were visible on the bone plates of the trabeculae, and the bone marrow was rich in hematopoietic tissue. These results demonstrate that the combination of core decompression and transplantation of HGF transgenic autologous BMSCs enhanced blood vessel regeneration and bone reconstruction in the ANFH model. This study provides experimental data that motivate possible clinical use of this therapeutic strategy.
Introduction
Avascular necrosis of the femoral head (ANFH) is a progressive pathological process that primarily afflicts people under 40 years of age. Without timely effective treatment, ANFH causes in situ avascular necrosis, and ultimately deforms the bone. The consequence is impaired hip joint function and permanent disability. [1] [2] [3] Whether the etiology of ANFH is traumatic or aseptic nontraumatic, the basic cause is a vicious cycle of elevated intraosseous pressure and obstructed blood supply in the femoral head. ANFH is considered irreversible, and any diagnostic or therapeutic strategy for ANFH is best introduced in the early stage. Early intervention will reduce intraosseous pressure and improve the blood supply to the necrotic femoral head. Osseous repair should be performed alongside supplemental interventions.
The most widespread procedure used to treat early stages of ANFH is core decompression of the hip, which involves drilling a small hole in diseased, necrotic bone. The goal of core decompression is to decrease the intraosseous pressure and allow the regrowth of healthy bone tissue. 4 Although the efficacy of this procedure remains controversial, it has been used for more than three decades. 5, 6 Reconstruction of blood circulation and stimulation of bone repair are important aspects of healing that support this surgical intervention. Thus, the combination of core decompression with the delivery of angiogenic or osteoinductive agents may improve the results of this surgical procedure in the future. 7 Vasodilatation and drug intervention therapy to activate blood and remove stasis are currently used to treat existing blood vessels, which results in disease remission but are not permanent solutions. However, the induction of blood vessel regeneration and the construction of a collateral circulation are the most effective ways to break the vicious pathological cycle of arterial disease or necrosis.
Cytokine supplement therapy is a potential treatment for peripheral arterial disease. Hepatocyte growth factor (HGF), originally purified and cloned as a mitogen for hepatocytes, 8, 9 is a novel member of the endotheliumspecific growth factors, and it can stimulate angiogenesis. Interestingly, HGF can stimulate a significantly higher level of DNA synthesis than basic fibroblast growth factor or vascular endothelial growth factor (VEGF). Comparatively, HGF is the most potent stimulator of endothelial cell growth. 10, 11 Laboratory animals with induced acute hepatic or renal injury showed much less histological damage and more satisfactory organ function after treatment with HGF. This putative anti-cell death function of HGF was further supported by subsequent studies with renal epithelial cells and neurons, 12, 13 as well as hepatocytes. 14, 15 Due to its ability to prevent a decrease in DNA synthesis and cell death in endothelial cells under serum-free treatment, 16 HGF should be reclassified as a new growth factor with anticell death actions. With these characteristic effects on cell survival, HGF therapy may be a useful therapeutic strategy for ANFH.
Bone marrow stromal stem cells (BMSCs) are pluripotent cells 17 that secrete large amounts of growth factors and angiogenic factors. BMSCs are bone progenitor cells with excellent potential for differentiation into osteoblasts 18, 19 that can restore bone tissue. 20 BMSCs can be easily isolated from bone and transfected with an exogenous gene. Moreover, autotransplantation of BMSCs induces no immunological rejection. For these reasons, BMSCs are regarded as the seed cells with the most potential for bone tissue engineering in the clinical context. 21, 22 Our study used recombinant adenovirus carrying the human HGF gene in the AdMax adenovirus vector system to transfect the second generation of autologous BMSCs in vitro. Transgenic BMSCs strongly expressing HGF protein were used as seed cells, and mixed with medical fibrin glue (FG), which functioned as a scaffold.
In a rabbit model of hormone-induced early ANFH, the BMSC-FG mixture was transferred into the necrotic femoral head under computed tomography (CT) control during core decompression. To evaluate therapeutic effects, pathological changes were observed with multiple imaging techniques. This study provides evidence for motivating ultimate clinical use of this stem-cell strategy.
Results

Transfection of recombinant adenovirus and expression of HGF in BMSCs
The infectious titer of adenoviral vectors carrying human HGF gene (Ad-HGF) was 2.6 Â 10 10 TCID 50 ml À1 and the high-performance liquid chromatography purity was greater than 95% ( Figure 1a ). HGF expression in BMSCs was confirmed at the mRNA level by a single 2.2-kb band after reverse transcription-PCR assay. There was no corresponding band amplified from nontransfected BMSCs (Figure 1b) . The transfection efficacy of Ad-GFP was about 98% at a multiplicity of infection of 300, assayed by FACS (Figure 1c) .
The HGF protein expressed by HGF transgenic BMSCs was secreted into the culture supernatant. The expression peak occurred at 48 h after transfection, and the expression level was 133 ng ml
À1
. HGF protein expression and secretion was observed for 2 weeks (Figure 2) . Cell-cycle analysis demonstrated that Ad vector transfection does not affect the cell cycle of the BMSCs, regardless of the exogenous gene (Table 1) . These results Figure 3 ). Normal (control) femoral heads were symmetrical, the joint surface was distinct and the cortex was smooth and intact. There was no change in the texture of cancellous bone, and the epiphyseal line was clear. By contrast, femoral heads subjected to induced ANFH group showed multiple spot-like low-density areas of structural change. The bone cortex was thinner, the epiphyseal line was blurred and osteoporosis was evident. In the transgenic BMSC group, the articular cavity was reduced and the spot-like or line-like high-signal area in the femoral head was lower than that in the core decompression-alone group. In the transgenic BMSC-FG group, femoral heads were symmetrical and the high-signal area was even lower than that in the transgenic BMSC group (Figure 4) .
Magnetic resonance imaging. In normal bone, femoral heads were symmetrical. In FS-T2WI, the high-level signal of fat under the cortex of the femoral head was inhibited and showed a low-level signal. In the ANFH group, magnetic resonance imaging (MRI) examination of the femoral head showed a larger articular cavity than in normal bone. The high-level FS-T2WI signal at the metaphyses suggested edema in the bone marrow. The cancellous bone of the femoral head appeared with irregular spot-like or line-like patterns of structural changes in the high-level signal image. In the core decompression-alone group, the spot-like or line-like high-signal area was relatively obvious. In the transgenic BMSC group, the articular cavity and the spot-like or linelike high-signal area was somewhat reduced. The spotlike low-density area in the transgenic BMSC-FG group was lower than that in the transgenic BMSC group, but not significant (P40.05). Both the transgenic BMSC group and the transgenic BMSC-FG group showed a reduced femoral head necrosis volume (o5%) compared with the ANFH group (10%), and this difference was significant (Po0.05). Core decompression alone did not show any difference from ANFH ( Figure 5 ).
CT perfusion imaging. In the normal group, femoral heads appeared symmetrical. Blood volume (BV) was also relatively high and became red. Femoral heads in the ANFH group were also highly symmetrical, but the BV was reduced to about 35% of that the normal group (Po0.05) and was blue. The femoral heads of the core decompression-alone group had increased BV compared with that of the ANFH group, and the proportion of the red/green area was increased, but there was no significant difference between these two groups. The BV of the femoral heads in the transgenic BMSC group was Figure 3 Core decompression guided by CT. The hips were visualized by CT (left). After the animals were anesthetized, the trocar was applied to puncture through skin and along the medial side of the great trochanter on the femoral head (right). The tip of the needle is located in the femoral head. Core decompression and delivery of BMSCs ensued.
Treating ANFH with HGF-transgenic BMSCs Q Wen et al higher than that of the core decompression-alone group (Po0.05), and was red. The BV of both femoral heads in the transgenic BMSC-FG group was similar to that of the normal group (P40.05) and was not significantly different from the transgenic BMSC group (P40.05) ( Figure 6 ).
Histopathological assessment
Ink artery infusion angiography. In the normal femoral head, the medullary cavity was rich in capillaries that formed a network. The vessels in the network were patent, and small vessels were abundant. In contrast, femoral heads in the ANFH group showed fewer blood vessels, and the capillary network was sparse. The blood vessels appeared obstructed, and the shallowlayer vessels under the joint surface of the femoral head had almost disappeared. Compared with the normal group, the number of unobstructed blood vessels decreased by 82%. In the core decompression-alone group, there were twofold more unobstructed blood vessels than in the ANFH group. However, there was still obvious thrombosis in the core decompression-alone group. In the transgenic BMSC group, the blood vessels under the cartilage were reconstructed and there were large recovery blood vessels in the metaphyses.
In the transgenic BMSC-FG group, blood vessels were almost fully reconstructed and were distributed evenly and abundantly ( Figure 7) . Interestingly, the number of unobstructed blood vessels in the BMSC-FG group was more than threefold greater than those in the ANFH group (Po0.05). There was no significant difference in the number of unobstructed blood vessels between the two BMSC transplantation groups (P40.05).
Histopathological observations. The periosteum of the normal group femoral heads was smooth, and the Treating ANFH with HGF-transgenic BMSCs Q Wen et al cartilage cells were in a tidy arrangement. The trabeculae were intact, and their arrangement was regular, compact and full. The bone cells in the trabeculae were clearly visible and there were few empty bone lacunae. The osteoblasts were columnar, cuboidal or spindle shaped and distributed along the trabeculae in strings. There were abundant medullary hematopoietic cells and small fat cells, and the cell morphology was normal. The ANFH group showed multiple differences from the normal group. The periosteum of the femoral head was incomplete and the cartilage cells were partly shed. The bone marrow cells were also decreased to nearly 30% of values seen in the normal group (Po0.05). There were few trabeculae, which were thin, showed disordered texture and were often broken into fragments. The nuclei of the bone cells were condensed. The empty lacunae in the trabeculae increased nearly onefold compared with the normal group (Po0.05). Few spindle-shaped osteoblasts were distributed along the trabeculae. The medullary hematopoietic areas were poorly organized and had fewer cells, a sparse capillary network and partly obstructed blood vessels. The fat cells were larger and had fused together into bubbles.
Compared with the ANFH group, the core decompression-alone group showed a somewhat decreased number of empty lacunae, but the effect was not significant for this observation period (P40.05). Metaphyseal osteoblasts had proliferated greatly and new bone had been generated. The hematopoietic tissue was scarce, predominantly in fat cells, and had no significant difference compared with the ANFH group (P40.05).
In the transgenic BMSC group, the trabeculae were generally in a tidy arrangement; compared with the ANFH group, the bone matrix was increased, and the number of empty bone lacunae had decreased. Newly generated capillaries were visible on the bone plate, and there were many osteoblasts at the edges of the trabeculae.
In the transgenic BMSC-FG group, the trabeculae were also in a tidy arrangement and there was obvious new bone. Newly generated capillaries were visible on the bone plate of the trabeculae. There was abundant hematopoietic tissue in the bone marrow and expansion of new blood vessels (Figure 8 ). In general, transgenic BMSC groups showed a significant decrease in the number of empty lacunae (Po0.05, compared with the ANFH group). Although the level of empty lacunae in the BMSC groups was not the same as those in the normal group, they were very low. The number of bone marrow hematopoietic cells in both the transgenic BMSC group and the transgenic BMSC-FG group were also very close to measures in the normal group (P40.05).
Extracellular signal-regulated kinase (ERK)-1/2-positive bone marrow cells in the ANFH group were only 37.5% of measures in the normal group. In the core decompression-alone group, the number of bone marrow cells expressing ERK1/2 was nearly twofold higher than those in the ANFH group, slightly higher than the normal groups. However, there was no significant difference between these three groups (P40.05). Interestingly, both transgenic BMSC groups showed a significantly increased number of ERK1/2-positive bone marrow cells compared with the three other groups. In addition, FG compound made no difference in this measure, as confirmed by statistical comparison (P40.05) (Figure 9 ).
Discussion
Taken together, our findings suggest that animals at an early stage of ANFH may recover healthy tissue with core decompression therapy in conjunction with BMSC transplantation. CT and MRI examination showed the differences in femoral head configuration among the different treatment groups. Radiology findings suggested that the animals in ANFH groups had stage-I or -II osteonecrosis of the femoral head, according to the system of the Association Research Circulation Osseous. CT perfusion imaging demonstrated changes in BV, with increases in the ANFH group, and comparative improvements in the two transgenic BMSC groups.
Consistent with the changes in the femoral head configuration shown by radiological scans, histopathological assays demonstrated a profound change in the blood flow, hematopoietic cell number in the bone marrow and bone cells in the trabeculae of BMSC-treated groups. The results showed that serum-and hormoneinduced pathologies in the ANFH model can be alleviated by core decompressions. Such pathologies include blood vessel obstruction, proportions of hematopoietic cells in the bone marrow and bone cells in the trabeculae. These ANFH-associated changes may be rectified to some extent after core decompression treatment, and particularly when it is supplemented with implantation of transgenic BMSCs.
In 2002, Valérie Gangji et al. 23 applied core decompression and implantation of autologous bone-marrow mononuclear cells to treat 13 patients (18 hips) with the Association Research Circulation Osseous stage-I or II necrosis of the femoral head. After 24 months, there was a significant reduction in pain measured with visual analog scale (P ¼ 0.021) and in joint symptoms measured with the Lequesne index (P ¼ 0.001) and the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis index (P ¼ 0.013). The ratio of the volume of necrotic lesion to that of the whole femoral head was significantly decreased by a mean of 35% in the bonemarrow-graft group after 24 months (P ¼ 0.001). The core decompression-alone group increased by a mean of 23%. The researchers thought this finding suggested that necrotic lesions might be reversible to some extent. On the basis of this successful case, we further tested therapeutic improvements for human ANFH and evaluated it on the rabbit model of early-stage ANFH. Gene therapy, stem cell transplantation and tissue engineering have been rationally combined in our study. Simultaneous with physical decompression, the HGF secreted by the transplanted BMSCs was released in a sustained way from the FG, and induced the local regeneration of new blood vessels and the construction of a collateral circulation. Blood supply was improved in the femoral head. Locally, BMSC could be induced to differentiate into osteoblasts to repair the necrotic bone tissue.
Our study integrates core decompression, vascular regeneration and bone reconstruction, and provides a new therapeutic mode for ANFH. To date, no other report of a similar therapeutic model exists. The therapeutic efficacy of transgenic BMSC treatment is evidenced by the following three sets of data. (1) Radiological scans showed a difference in the normal, ANFH and treated femoral heads of the rabbit early ANFH model. But after treatment, the signals in the As early diagnosis and intervention for ANFH is extremely important, we were motivated to establish the rabbit model of hormone-induced early ANFH. We used horse serum to cause vasculitis, and combined it with a large dose of prednisolone acetate to inhibit the synthesis of collagen and elastic protein. 24 The subsequent aggravated contraction of the blood vessels with vasculitis, platelet aggregation and necrosis of endothelial cells causes the breakdown and obstruction of small arteries.
These processes led eventually to avascular necrosis in the bone. Our rabbit model-induced ANFH results are consistent with the imaging characteristics of early ANFH according the system of the Association Research Circulation Osseous, and can also be classified as stages I and II according to the clinical Ficat stage criteria. Our model resembles the clinical disease progress of human hormone-induced ANFH, because large doses of hormone used to treat patients with other diseases such as arthritis or vasculitis can eventually cause ANFH. For example, systemic lupus erythematosus is associated with a high incidence rate of ANFH due to the consequence of necessary hormone therapy. 25 Angiogenic factors are a group of cytokines that induce the generation of blood vessels. Of the numerous angiogenic factors, VEGF is known to be the most potent and is used most frequently in the clinical context. Some researchers have tried to introduce VEGF to induce new Treating ANFH with HGF-transgenic BMSCs Q Wen et al blood vessels in ANFH, but have been unsuccessful, possibly for two reasons. First, no effective means of decompression has been adopted for these schemes. Therefore, it is difficult for an ideal network of new blood vessels to be generated, in the same way that it is difficult for bamboo shoots under a huge stone to emerge from the ground. Second, VEGF also increases vascular permeability, which in turn causes tissue edema, and further increases intraosseous pressure. 26, 27 This increased pressure undermines the necessary effort toward decompression in ANFH. Another angiogenic factor often used in the clinical setting is basic fibroblast growth factor. However, it enhances the proliferation of smooth muscle in blood vessels, as well as that of vascular endothelial cells, which may cause arterial stenosis. 28 Consequently, it is critical to choose an appropriate angiogenic factor for ANFH treatment.
Hepatocyte growth factor is a multifunctional cytokine produced by mesenchymal cells, which also has a potent angiogenic function. HGF can also inhibit cellular apoptosis and alleviate tissue fibrosis. [29] [30] [31] As HGF has shown excellent potential for application in therapies for avascular cardiopathy and peripheral arterial occlusion, [32] [33] [34] it is likely to be an excellent angiogenic factor in therapy for ANFH. The main signal pathway of HGF function is the activation of ERK1/2, which furthers reduction of necrotic cell death, as well as apoptotic cell death. 35 In our study, the level of ERK1/2 activation was relatively low in the normal group and the ANFH group, increased somewhat in the core decompression-alone group and significantly increased in the two transgenic BMSC groups. This result suggests that in the normal condition without stimulation, ERK1/2 is not popularly activated. Once some kind of interference such as core decompression was taken, and the intraosseous pressure was relatively decreased, ERK1/2 was stimulated, but the level was not enough to support the recovery of the entire femoral head. Overexpression of HGF by transgenic BMSCs likely increased the activation level of ERK1/2. In these treatment groups, the recovered blood circulation and new bone formation were significant. Therefore, activation of ERK1/2 by HGF in endothelial cells and osteocytes supports a hypothesis that HGF signaling promotes the proliferation of endothelial cells and osteocytes. In 2004, Yang Cao et al. 36 alleviated necrosis in rabbit femoral heads after transferring a mixture containing collagen and a eukaryotic expression plasmid with VEGF165 and basic fibroblast growth factor genes. However, there is still no report on the treatment of ANFH with HGF.
A technique for local drug delivery with high efficiency is required for the reconstruction of new vascular networks in femoral heads. A local sustained delivery technique can partly achieve this goal, but a large amount of drug still enters the systemic circulation, and it is difficult to maintain an effective working concentration at the desired site. Stem cell gene therapy technology has developed rapidly in recent years and There is precedent for autologous BMSC transplantation in humans with ANFH. In 2006, Wang Wu-Zhou et al.
38 treated 19 patients suffering from grades I-III ANFH with a combination of core decompression and autologous BMSC transplantation. The postoperative followup was 12 months. Reexamination with MRI showed that the average necrotic area of the femoral heads decreased from 31.88 to 13.18%. The improvement in patients with grades I and II ANFH was especially notable; the pain in the hip joint was relieved 3 weeks after the operation, peripheral function began to recover 6 months after transplantation and the Harris score for the hip joint increased from 58.74 to 86.76. This finding in humans demonstrates the efficiency and safety of this therapy using autologous BMSCs for the treatment of ANFH. At present, results obtained with the treatment of early ANFH with autologous BMSCs are encouraging.
Our study elaborates on these clinical findings with the use of transgenic BMSCs in an animal model. There are significant advantages with the use of HGF transgenic BMSCs over BMSCs without exogenous gene transfer. One is that transgenic BMSCs have the capacity to promote bone generation and at the same time secrete HGF that induces blood vessel generation and improves blood supply in the femoral head. Another is that HGF has chemotactic effects on BMSCs, and locally secreted high HGF concentrations can not only sustain BMSCs in the necrotic area, but also promote BMSC differentiation into osteoblasts. A third advantage is that HGF inhibits BMSC apoptosis, and the blood vessels induced by HGF can improve the environment for BMSCs, by increasing the survival rate of transplanted cells. All of these HGF advantages support an increased therapeutic efficiency.
There are some mechanics to consider when developing the BMSC transplantation model. If HGF transgenic BMSCs are transplanted into the high-pressure femoral necrotic area through the tunnel of the core decompression, the cells may drain away with the release of the intraosseous pressure. However, mixing the cells with medical FG before transplantation can effectively solve this problem. FG has excellent histocompatibility and plasticity and its molecular structure favors cell adhesion. It can quickly mold in vivo and is easily degraded and absorbed. The rate of FG degradation can be regulated by modulating the concentration of fibrinogen or adding aprotinin. For these reasons, FG is an excellent supporting material for seed cells in tissue engineering, [39] [40] [41] and particularly for ANFH, which may require added support for transplanted BMSCs. When HGF-transgenic BMSCs are mixed with FG in an appropriate proportion, the gel structure formed also functions as a sponge-like drug vehicle that could release secreted HGF protein slowly and maintain a desired local concentration.
Both the study of Peng Song-Lin et al. 42 and our primary study found that the mixture of BMSCs and FG in vitro had no effect on the growth, proliferation or differentiation of the BMSCs. In our study, the concentration of fibrinogen was adjusted to 80 mg ml
À1
, mixed with 2000 kIU ml À1 aprotinin, which slowed the rate of FG degradation and maintained the effective period at 4 weeks, consistent with the time necessary for exogenous gene expression by Ad-HGF-transfected BMSCs (data not shown). Although in our study there was no significant difference between the transgenic BMSC group and the transgenic BMSC-FG group, the transgenic BMSC-FG group achieved relatively better therapeutic effects. This finding suggests that FG could be used as an effective alternative measure for transplantation of BMSCs.
In our rabbit animal model study, the surgical therapeutic intervention was conducted only once. Although the Ad vector could not recombine into the BMSC genome for long-term expression, our study showed that it could persist for at least 1 month (data not shown). As the therapeutic goal of our study is the early-stage ANFH, the disease condition is not very severe. Our results demonstrated that a single delivery of Ad-HGF-transgenic BMSCs could still achieve relatively good effects. However, multiple stem-cell deliveries may deliver better therapeutic results. We are currently considering improvements in the transplantation therapy.
Our demonstration in a rabbit model of hormoneinduced early ANFH demonstrated the feasibility and safety of the transgenic BMSC therapeutic strategy. The combined results from CT, MRI, CT perfusion imaging, ink artery infusion angiography and histology showed that this method can effectively promote vascular regeneration and bone reconstruction in necrotic femoral heads. In addition, therapeutic efficacy with transgenic BMSC was better than in the core decompression-alone group. This study provides the basis for the development of an original drug for the early treatment of ANFH and constitutes original independent intellectual property. On the basis of these results, we are further studying the efficacy of this method in a beagle dog model. We are tracking the location and differentiation of BMSCs to better understand the path they follow in vivo.
Materials and methods
Animals and treatment groups
Thirty healthy adult male New Zealand rabbits with an average weight of 3 kg were provided by the Experimental Animal Center of Nanfang Hospital (Guangzhou, Guangdong, China) and maintained under specific pathogen-free conditions. Animals were randomly assigned to five treatment groups. Five rabbits were set aside as no-treatment unoperated normal controls. The remaining 25 animals were induced with ANFH (methods below). Of those 25, sixteen survived and were randomly assigned to two groups of 8. Five received no therapy (ANFH group). Eight animals received different treatment in each hip. One set of hips were treated with only core decompression (core decompression-alone group). The other set was treated with a combination of core decompression and transplantation of HGF Treating ANFH with HGF-transgenic BMSCs Q Wen et al transgenic autologous BMSCs (transgenic BMSC group). The remaining eight animals were treated with the combination of core decompression and transplantation of HGF transgenic autologous BMSCs mixed with FG in both hips (transgenic BMSC-FG group) ( Table 2) .
Adenoviral vector preparation
Replication-deficient recombinant adenoviral vectors carrying either human HGF gene (Ad-HGF) or the green fluorescent protein gene (Ad-GFP) were constructed with AdMax system (Microbix Biosystems Inc., Toronto, Ontario, Canada). Both vectors were purified with cesium chloride (SINOJIE (HK) Ltd, Shanghai, China) gradient centrifugation. 43 A tissue culture infectious dose (TCID 50 ) assay was used to determine the virus titer. The purity of Ad-HGF was determined by a high-performance liquid chromatography assay.
BMSC preparation BMSC culture and transfection. Bone marrow (3 ml) was aspirated from the bilateral posterior superior iliac spine and placed into high-glucose Dulbecco's modified Eagle's medium (GIBCO BRL, Gaithersburg, MD, USA) containing 50 U ml À1 of heparin sodium (Xian Tianyi Biotechnology Co. Ltd., LinTong, Shanxi, China) and 10% fetal calf serum (Hyclone Ltd, Logan, UT, USA). The dissociated cell mixture was agitated then centrifuged at 800 g for 5 min. The cell pellet was resuspended, then cultured in high-glucose Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and 2 mM L-glutamine (Invitrogen, Carlsbad, CA, USA) at 37 1C. After 72 h, nonadherent debris was removed and adherent cells were cultured to the second generation.
Bone marrow stromal stem cells were infected with Ad-GFP within a multiplicity of infection range of 50-400. The transfection efficiency was determined by flow cytometry (FACSCalibur, Becton Dickinson and Co., Franklin Lakes, NJ, USA). The rabbit model of early ANFH. Artificial ANFH was induced in rabbits by the following method. A combination of horse serum (Hyclone) and prednisolone acetate (Pharmacia & Upjohn Co., Kalamazoo, MI, USA) was injected over time to create a model of early ANFH. First, horse serum (10 ml kg À1 ) was injected through an ear vein. Two weeks later, 5 ml kg À1 of horse serum was injected in the same way once a day for 2 days. Two weeks later, 7.5 mg kg À1 of prednisolone acetate was injected into the abdomen twice a week for 2 weeks. At the time of injecting the hormone, 200 000 U of penicillin was injected into the buttock of each animal. At the end of week 5 after the hormone injection, the animals were examined with several imaging techniques (described below) to establish baseline of disease. During the establishment of ANFH model, four rabbits died of infection.
Transplantation of autologous BMSCs to ANFH model Preparation of transfected BMSCs and medical FG.
Fibrin glue (FG) solution contained two components. The first is solution I: 2000 kIU ml À1 aprotinin (Lanzhou Dadeli Biochemical Pharmaceutical Co. Ltd, Lanzhou, Gansu, China) was prepared at 37 1C in sterile water and used to dissolve freeze-dried human fibrinogen (Shanghai RAAS Blood Products Co. Ltd., Shanghai, . One milliliter of the cell suspension was centrifuged at 800 g for 5 min and the cell pellet was resuspended in 900 ml of solution I. This preparation of solution I with transfected BMSCs and FG and solution II would be mixed fully and was hereafter termed BMSC-FG.
Core decompression and transplantation of BMSCs to the femoral head. All animals receiving core decompression were anesthetized. A mixture of 1.5 ml of veterinary sumianxin II and 1 ml of atropine sulfate was injected into the buttock. The first dose was 0.7-0.8 ml kg À1 and a half-dose was injected 30-40 min later. Core decompression was then conducted under CT control with Somatom PLUS 4 CT scanner (Siemens, Erlangen, Germany). A custom-made trocar was applied to puncture the femoral head and conduct core decompression, as well as to deliver BMSCs or BMSC-FG mixtures. A disposable dispensing needle (1.2 Â 38 mm) was used as the puncture trocar sheath, with the needle matching the 18G OptiMed Vitesse biopsy gun (diameter 1.2 mm) as the trocar needle. Before use, the needle was shaped by a grinding wheel and sandpaper to neatly match the top-inclined plane of the trocar sheath with optimal smoothness and sharpness. In addition, puncture trocars were sterilized by soaking for 2 h in potentiated glutaraldehyde solution immediately before the operation. The femoral head was punctured once. For transgenic BMSC group, 10 6 cells in 100 ml high-glucose Dulbecco's modified Eagle's medium containing no fetal calf serum were transferred into the necrotic femoral head. For transgenic BMSC-FG groups, an aliquot (90 ml) of solution I containing suspended cells and 10 ml of solution II were transferred with a duplex syringe, through the tunnel of the core decompression. The animals were examined at the end of 4 weeks after decompression surgery.
Evaluation of treatment. All animals received CT perfusions and MRI examination. The treated animals were divided into scanning groups organized by hip treatment identity. Ink Artery Infusion Angiography was performed on the following subsets: four hips from the normal group (two animals), four hips from the ANFH group (two animals), four hips from the core decompression-alone group, four hips from transgenic BMSC group and eight hips from the transgenic BMSC-FG group. Histopathology and immunolabeling with ERK1/ 2 was performed on the following sets: six hips from the normal group (3 animals), six hips from the ANFH group, four hips from the core decompression-alone group, four from the transgenic BMSC group, and eight hips from the transgenic BMSC-FG group. The scans were analyzed by two different observers, each blind to treatment groups.
Conventional CT examination
Computer tomography examination was performed with a Lightspeed 16 spiral CT scanner (GE Company, New York, USA). The animals were anesthetized and fixed in the supine position on the operating board, and hip joints were positioned symmetrically and as laterally as possible. Transect scanning of the entire hip joint was performed, including the upper and lower edges. The scanning parameters were 100 kV and 220 mA. The combination detector was 16 Â 0.625 mm, the screw pitch was 0.625:1, the bed speed was 5.62 mm/r, the reconstruction layer was 1.25 mm thick and the diameter of field of view was 9.6 cm.
MRI examination
The examination was conducted using the Magnetom Vision PLUS 1.5 T superconducting MRI machine (Siemens). An orthogonal head coil was placed on the anesthetized rabbit, and the center of the coil was located on the hip joint. Fast spin echo was used. T2WI fatsuppression sequence (FS-T2WI) was collected twice in the coronal position. The layer thickness was 3 mm and the field of view was 100 Â 100 mm.
CT perfusion imaging
Cross sections of the hip joints were first scanned routinely. Layers that both included the femoral head and were thinner than 1 cm were chosen for rescan in the axial plane. The thickness of the layers were 2.5 Â 4 mm and the layers were scanned once every 2 s. Four milliliters of contrast reagent Iohexol (300 mg ml À1 ; Yangtze River Pharmacy Group, Taizhou, Jiangsu, China) was injected into an ear vein at a rate of 1.5 ml s
À1
, and the same layers were subjected to dynamic enhanced scanning 45 times in 90 s.
Ink artery infusion angiography and analysis
The animals were anesthetized as described in the core decompression section above and the abdominal aorta was exposed. After the blood was washed away with saline, a 7:3 v/v mixture of ink (Shanghai Hero Group Co. Ltd, Shanghai, China) and dextran (Shanghai Fu Min Pharmaceutical Factory, Shanghai, China) was injected into the aorta, until the skin of the bilateral crura and nails were uniformly black. The body was kept at 4 1C overnight, and the next day, the thighbones were removed and fixed in 4% paraformaldehyde (Tianjin Baishi Chemical Industry Co. Ltd, Tianjin, China) for 3 days. Then these bones were decalcified with 10% ethylenediamine tetraacetic acid disodium salt (Na 2 -EDTA, Jinhuada) in posphate-buffered saline (GIBCO BRL). The samples were dehydrated stepwise and turned transparent by exposure to dimethylbenzene (Jinhuada) and sodium salicylate (Jinhuada). Samples were then sectioned into 50-mm-thick layers and observed under a stereomicroscope. Configuration of the femoral head, blood distribution and growth condition were observed. The ratio of the area of ink artery to that of the whole femoral head was counted using at least five randomly selected fields per section.
Histopathology and immunohistochemistry
After euthanization by air injection through ear vein, both femoral heads including the metaphyses and Treating ANFH with HGF-transgenic BMSCs Q Wen et al thighbones were removed, observed by macrography, fixed and demineralized as described in the angiography section above. The samples were dehydrated stepwise, turned transparent by dimethylbenzene, embedded in wax, cut into 4 mm sections and mounted onto slides. The sections were stained with hematoxylin and eosin and observed under a microscope. Changes in the periosteum, cartilage, trabeculae and hematopoietic organization were observed. The number of empty lacunae and the bone marrow hematopoietic cells were counted at a Â 400 magnification, by at least five randomly selected fields per section. For immunolabeling of ERK1/2, the slides were incubated with mouse monoclonal anti-ERK1/2 (1:250) (sc-7383; Santa Cruz Biotechonology Inc., Santa Cruz, CA, USA) for 1 h, followed by incubation with biotinylated goat anti-mouse IgG working solution (BA1001, BOSTER bioengineering Co. Ltd, Wuhan, Hubei, China). Slides were then treated with streptavidin-biotin complex kit (SA2010, BOSTER) and the color was developed with 3,3 0 -diaminobenzidine (DAB). The number of ERK1/2-positive cells was counted at Â 600 magnification, by at least five randomly selected fields per section.
Statistical analysis
Data are described as the mean and the standard error of the mean. One-way ANOVA was used to determine the statistical significance. SPSS statistical software (version 16.0; SPSS, Chicago, IL, USA) was used. Po0.05 was considered as significant.
